DK0605193T3 - Anvendelse af benzothiophener til behandling af hypercholesterolæmi - Google Patents

Anvendelse af benzothiophener til behandling af hypercholesterolæmi

Info

Publication number
DK0605193T3
DK0605193T3 DK93310438T DK93310438T DK0605193T3 DK 0605193 T3 DK0605193 T3 DK 0605193T3 DK 93310438 T DK93310438 T DK 93310438T DK 93310438 T DK93310438 T DK 93310438T DK 0605193 T3 DK0605193 T3 DK 0605193T3
Authority
DK
Denmark
Prior art keywords
alkanoyloxy
substituted
unsubstituted
cycloalkanoyloxy
methoxy
Prior art date
Application number
DK93310438T
Other languages
Danish (da)
English (en)
Inventor
Larry John Black
Henry Uhlman Bryant
Raymond Francis Kauffman
George Joseph Cullinan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0605193T3 publication Critical patent/DK0605193T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Bipolar Transistors (AREA)
  • Semiconductor Lasers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK93310438T 1992-12-22 1993-12-22 Anvendelse af benzothiophener til behandling af hypercholesterolæmi DK0605193T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99522292A 1992-12-22 1992-12-22

Publications (1)

Publication Number Publication Date
DK0605193T3 true DK0605193T3 (da) 2003-03-31

Family

ID=25541537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93310438T DK0605193T3 (da) 1992-12-22 1993-12-22 Anvendelse af benzothiophener til behandling af hypercholesterolæmi

Country Status (28)

Country Link
US (1) US5464845A (ko)
EP (2) EP0605193B1 (ko)
JP (1) JP3197129B2 (ko)
KR (1) KR100278946B1 (ko)
CN (1) CN1043608C (ko)
AT (1) ATE233559T1 (ko)
AU (1) AU669235B2 (ko)
BG (1) BG61524B1 (ko)
BR (1) BR9305182A (ko)
CA (1) CA2112017C (ko)
CZ (1) CZ283863B6 (ko)
DE (1) DE69332735T2 (ko)
DK (1) DK0605193T3 (ko)
ES (1) ES2193142T3 (ko)
HU (1) HU223342B1 (ko)
IL (1) IL108042A (ko)
MY (1) MY109345A (ko)
NO (1) NO304924B1 (ko)
NZ (1) NZ250486A (ko)
PH (1) PH30430A (ko)
PL (1) PL177349B1 (ko)
RO (1) RO113806B1 (ko)
RU (1) RU2123335C1 (ko)
SG (1) SG52696A1 (ko)
SK (1) SK279271B6 (ko)
TW (1) TW383306B (ko)
YU (1) YU48918B (ko)
ZA (1) ZA939427B (ko)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
USRE38968E1 (en) 1992-07-28 2006-02-07 Eli Lilly And Company Methods for inhibiting bone loss using 6-hydroxy-2-(4-hydroxyphenyl)-benzo[b]thien-3-yl-4-[2-(piperidin-1-yl) ethoxyphenylimethanone hydrochloride
USRE39049E1 (en) 1992-07-28 2006-03-28 Eli Lilly And Company Methods for inhibiting bone loss
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5482950A (en) * 1993-10-15 1996-01-09 Eli Lilly And Company Methods for lowering serum cholesterol
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
CZ306394A3 (en) * 1993-12-14 1995-08-16 Lilly Co Eli Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
CN1095663C (zh) * 1993-12-21 2002-12-11 伊莱利利公司 抑制低密度脂蛋白氧化和动脉粥样硬化的方法
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
AU3953795A (en) * 1994-10-20 1996-05-15 Eli Lilly And Company Bicyclic neuropeptide y receptor antagonists
US6562862B1 (en) * 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5484808A (en) * 1995-02-09 1996-01-16 Eli Lilly And Company Methods of inhibiting cell-cell adhesion
AU5554996A (en) * 1995-04-21 1996-11-07 Eli Lilly And Company Benzothiophenes with novel basic side chains
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
US5726168A (en) * 1995-10-12 1998-03-10 Eli Lilly And Company Lipophilic benzothiophenes
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
JP2000506885A (ja) * 1996-03-19 2000-06-06 イーライ・リリー・アンド・カンパニー ３―［４―（２―アミノエトキシ）ベンゾイル］―２―アリール―６―ヒドロキシベンゾ［ｂ］チオフェンの合成
US6458811B1 (en) 1996-03-26 2002-10-01 Eli Lilly And Company Benzothiophenes formulations containing same and methods
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
CA2206752A1 (en) * 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
CA2214072C (en) * 1996-08-29 2006-11-14 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, processes, compositions, and methods
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
EP0979076A4 (en) * 1997-04-30 2003-03-19 Lilly Co Eli INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF BENZO b] THIOPHENES
CA2287918A1 (en) * 1997-04-30 1998-11-05 John Mcneill Mcgill Iii A regioselective alkylation process for preparing substituted benzo¬b|thiophenes
CA2231013A1 (en) * 1997-04-30 1998-10-30 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
JP2001522372A (ja) * 1997-04-30 2001-11-13 イーライ・リリー・アンド・カンパニー ベンゾチオフェンの製造方法
CA2236254A1 (en) * 1997-04-30 1998-10-30 David Warren Hoard Process for preparing benzo¬b|thiophenes
CA2287920A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company Intermediates and a process for preparing benzo¬b|thiophenes
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
US6096781A (en) 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
AP2002002555A0 (en) 1999-12-22 2002-06-30 Pfizer Prod Inc EP4 Receptor selective agonists in the treatment of osteoporosis.
EP1156120B1 (en) * 2000-05-08 2006-11-22 Pfizer Products Inc. Enzymatic resolution of selective estrogen receptor modulators
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
US20060106010A1 (en) * 2003-05-27 2006-05-18 Black Larry J Methods for inhibiting bone loss
BRPI0417621A (pt) * 2003-12-17 2007-04-10 Pfizer Prod Inc terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
CA2694642C (en) 2007-07-27 2017-05-16 Container Stuffers, Llc Cargo loader
CN101669557B (zh) * 2009-08-20 2012-07-25 杭州六易科技有限公司 一种清热解毒凉茶的制作方法
JPWO2016021706A1 (ja) * 2014-08-08 2017-05-25 カズマパートナーズ株式会社 縮合複素環化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
US5441964A (en) * 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene

Also Published As

Publication number Publication date
CN1094042A (zh) 1994-10-26
CA2112017A1 (en) 1994-06-23
IL108042A (en) 1998-01-04
TW383306B (en) 2000-03-01
HU223342B1 (hu) 2004-06-28
CN1043608C (zh) 1999-06-16
SK142193A3 (en) 1995-01-12
CA2112017C (en) 2005-06-14
PL301579A1 (en) 1994-06-27
JP3197129B2 (ja) 2001-08-13
NO934740D0 (no) 1993-12-21
BR9305182A (pt) 1994-08-16
RO113806B1 (ro) 1998-11-30
KR100278946B1 (ko) 2001-01-15
ZA939427B (en) 1995-06-15
ES2193142T3 (es) 2003-11-01
IL108042A0 (en) 1994-04-12
HUT69686A (en) 1995-09-28
DE69332735T2 (de) 2003-10-23
YU79893A (sh) 1997-05-28
CZ279093A3 (en) 1994-07-13
NO304924B1 (no) 1999-03-08
EP0605193A1 (en) 1994-07-06
SK279271B6 (sk) 1998-08-05
YU48918B (sh) 2002-11-15
AU669235B2 (en) 1996-05-30
PH30430A (en) 1997-05-09
DE69332735D1 (de) 2003-04-10
NZ250486A (en) 1997-06-24
HU9303676D0 (en) 1994-04-28
NO934740L (no) 1994-06-23
ATE233559T1 (de) 2003-03-15
EP1238667A3 (en) 2003-12-10
MY109345A (en) 1997-01-31
JPH06234632A (ja) 1994-08-23
KR940013501A (ko) 1994-07-15
AU5257893A (en) 1994-07-07
EP1238667A2 (en) 2002-09-11
CZ283863B6 (cs) 1998-06-17
BG61524B1 (bg) 1997-11-28
RU2123335C1 (ru) 1998-12-20
PL177349B1 (pl) 1999-10-29
SG52696A1 (en) 1998-09-28
EP0605193B1 (en) 2003-03-05
BG98317A (en) 1995-02-28
US5464845A (en) 1995-11-07

Similar Documents

Publication Publication Date Title
DK0605193T3 (da) Anvendelse af benzothiophener til behandling af hypercholesterolæmi
TR199500954A1 (tr) Yeni pirokarbazoller.
NO962415D0 (no) Metode for nedsettelse av serumkolesterolnivåer med 2,6-dialkyl-4-silylfenoler
DK0404359T3 (da) Dibenzothiazepin-derivater, der er nyttige som antispasmodiske midler
EP0436734A4 (en) New aminopiperazine derivatives
DE69410509D1 (de) Benzoxazinderivate, deren Herstellung und deren Verwendung in Therapie
AU7452791A (en) Novel diphenylthyazole derivative
DE3862791D1 (de) N-phenylethylaminoalkyl-benzamide als antiarrhythmische mittel.
NO20000750D0 (no) Fremgangsmåte for å redusere blodplatetall
PT77466B (de) Neue 4-hydroxy-2h-1,2-benzothiazin-3-carboxamid-1,1-dioxide verfahren zu ihrer herstellung ihre verwendung und diese verbindungen enthaltende arzneimittel
ATE117682T1 (de) Substituierte benzothiazolinone, ihre herstellung und sie enthaltende pharmazeutische zusammenstellungen.
PH18574A (en) Substituted 11-oxo-11h-pyrido 2,i-h -quinazoline derivatives,pharmaceutical compositions containing them and method of use thereof